148 related articles for article (PubMed ID: 36727900)
1. Comparison of 68 Ga-DOTATATE PET/CT and 68 Ga-Pentixiafor PET/CT Imaging in a Case of Merkel Cell Carcinoma.
Rao Z; Zhang Y; Liu L; Wang M; Zhang C
Clin Nucl Med; 2023 Apr; 48(4):339-341. PubMed ID: 36727900
[TBL] [Abstract][Full Text] [Related]
2. Comparison of (18)F-FDG PET/CT and (68)Ga-DOTATATE PET/CT imaging in metastasized Merkel cell carcinoma.
Epstude M; Tornquist K; Riklin C; di Lenardo F; Winterhalder R; Hug U; Strobel K
Clin Nucl Med; 2013 Apr; 38(4):283-4. PubMed ID: 23429397
[TBL] [Abstract][Full Text] [Related]
3. False-Positive Uptake in Splenic Hemangioma on 68 Ga-DOTATATE PET/CT.
Zhu B; Yoon E; Mahajan S; Kranz AO
Clin Nucl Med; 2023 Jun; 48(6):518-519. PubMed ID: 37075248
[TBL] [Abstract][Full Text] [Related]
4. 68Ga-DOTATATE-PET/CT positive metastatic lymph node in a 69-year-old woman with Merkel cell carcinoma.
Schneider C; Schlaak M; Bludau M; Markiefka B; Schmidt MC
Clin Nucl Med; 2012 Nov; 37(11):1108-11. PubMed ID: 22996252
[TBL] [Abstract][Full Text] [Related]
5. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor imaging with [
Zhao L; Pang Y; Wang Y; Chen J; Zhuang Y; Zhang J; Zhao L; Sun L; Wu H; Chen X; Lin Q; Chen H
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1360-1373. PubMed ID: 34665275
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
8. Differential Detection of Hepatic Metastases on 68 Ga-DOTATATE PET/CT and 177 Lu-DOTATATE SPECT/CT.
Zahed H; Beauregard JM; Abikhzer G; Rush C; Probst S
Clin Nucl Med; 2023 Jan; 48(1):e12-e15. PubMed ID: 36240803
[TBL] [Abstract][Full Text] [Related]
9. The utility of
Shell J; Tirosh A; Millo C; Sadowski SM; Assadipour Y; Green P; Patel D; Nilubol N; Kebebew E
Eur J Radiol; 2019 Mar; 112():130-135. PubMed ID: 30777201
[TBL] [Abstract][Full Text] [Related]
10. Increased Vertebral Gallium-68-DOTATATE Activity on Positron Emission Tomography-Computed Tomography in Merkel Cell Carcinoma: Not Always Metastasis.
Purohit K; Minassian G; Purohit L; Peyster R; Bluestone A
Cureus; 2023 May; 15(5):e39427. PubMed ID: 37362502
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
13. A prospective head-to-head comparison of
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
[TBL] [Abstract][Full Text] [Related]
14. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
[TBL] [Abstract][Full Text] [Related]
15. Head-to-Head Comparison of
Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
[TBL] [Abstract][Full Text] [Related]
16. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
17. Differences in tumor-to-normal organ SUV ratios measured with 68 Ga-DOTATATE PET compared with 177 Lu-DOTATATE SPECT in patients with neuroendocrine tumors.
Wong KK; Frey KA; Niedbala J; Kaza RK; Worden FP; Fitzpatrick KJ; Dewaraja YK
Nucl Med Commun; 2022 Aug; 43(8):892-900. PubMed ID: 35703269
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Esophageal Adenocarcinoma Showing 68 Ga-DOTATATE Uptake.
Fılızoglu N; Ozguven S
Clin Nucl Med; 2023 Nov; 48(11):e535-e536. PubMed ID: 37756476
[TBL] [Abstract][Full Text] [Related]
19.
AlSadi R; Maaz AUR; Bouhali O; Djekidel M
J Nucl Med Technol; 2023 Jun; 51(2):140-146. PubMed ID: 37192823
[No Abstract] [Full Text] [Related]
20. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]